1. Prospective study of cenobamate on cognition, affectivity, and quality of life in focal epilepsy
- Author
-
Judit Catalán‐Aguilar, Kevin G. Hampel, Irene Cano‐López, Mercedes Garcés, Alejandro Lozano‐García, Paula Tormos‐Pons, Esperanza González‐Bono, and Vicente Villanueva
- Subjects
cenobamate ,cognition ,drug‐resistant epilepsy ,negative affectivity ,quality of life ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Abstract Objective Cenobamate is a recently approved antiseizure medication that proved to be safe and effective in randomized controlled trials. However, little is known about its impact on some areas frequently affected by epilepsy. For this reason, we explored the effects of cenobamate on cognitive performance, as well as on negative affectivity and quality of life in a sample of patients with drug‐resistant epilepsy. Methods Two prospective cohort studies were carried out. In Study 1, 32 patients (22 men and 10 women) underwent a baseline (T0) and a short‐term (T1) neuropsychological assessment after 3 months of cenobamate administration. In Study 2, 22 patients (16 men and 6 women) from the T1 sample also underwent a baseline and a follow‐up evaluation (T2) 6 months after T0. Results No significant differences were found in cognitive variables, negative affectivity, and quality of life either in Study 1 or Study 2. Similarly, based on the reliable change index, it was found that most patients showed no changes in these variables. Significance These results suggest that cenobamate is a safe antiseizure medication in terms of cognition, negative affectivity, or quality of life since no adverse events have been found after 3 and 6 months of treatment. Plain Language Summary Cenobamate is a new antiseizure medication. In patients with epilepsy, cenobamate seems to not affect cognition, anxiety, depression, or quality of life.
- Published
- 2024
- Full Text
- View/download PDF